Agile Therapeutics Inc Revenue Growth Rates (AGRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Agile Therapeutics Inc  (AGRX)
 

AGRX's Revenue Growth by Quarter and Year

Agile Therapeutics Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AGRX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 5.08
1st Quarter March 5.04
FY 10.12





AGRX Revenue second quarter 2024 Y/Y Growth Comment
Agile Therapeutics Inc reported decrease in Revenue in the second quarter 2024 by -2.31% to $ 5.08 millions, from the same quarter in 2023.
The decrease in the second quarter 2024 Agile Therapeutics Inc's Revenue compares unfavorably to the Company's average Revenue doubling of 207.2%.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 157 other companies have achieved higher Revenue growth. While Agile Therapeutics Inc' s Revenue decline of -2.31% ranks overall at the positon no. 2489 in the second quarter 2024.


AGRX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - -14.5 % 164.9 % 101.33 %
3rd Quarter September - 106.33 % 132.56 % -
2nd Quarter June -2.31 % 144.13 % 78.99 % -
1st Quarter March 32.28 % 116.48 % 1366.67 % -
FY   - 70.98 % 164.96 % -

Financial Statements
Agile Therapeutics Inc's second quarter 2024 Revenue $ 5.08 millions AGRX's Income Statement
Agile Therapeutics Inc's second quarter 2023 Revenue $ 5.20 millions Quarterly AGRX's Income Statement


AGRX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - -44.75 % 33.33 % 17.05 %
3rd Quarter September - 19.04 % 40.85 % 8.4 %
2nd Quarter June 0.79 % 36.48 % 21.02 % 891.67 %
1st Quarter March 47.37 % -4.75 % 16.56 % -84 %
FY (Year on Year)   - 70.98 % 164.96 % -


Back to AGRX Growth rate Comparisons >> Back to AGRX Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #158
Healthcare Sector #411
Overall #2489

Revenue Y/Y Growth Statistics
High Average Low
1418.1 % 207.2 % -14.37 %
(Dec 31 2022)   (Jun 30 2024)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #158
Healthcare Sector #411
Overall #2489
Revenue Y/Y Growth Statistics
High Average Low
1418.1 % 207.2 % -14.37 %
(Dec 31 2022)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Agile Therapeutics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
921.55 % 73.48 % -84.51 %
(Jun 30 2021)  


AGRX's II. Quarter Q/Q Revenue Comment
Agile Therapeutics Inc achieved in the II. Quarter 2024 below company average Revenue growth of 0.79% quarter on quarter, to $ 5.08 millions.

Within Major Pharmaceutical Preparations industry 157 other companies have achieved higher Revenue quarter on quarter growth. While Agile Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 2425.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #158
Healthcare Sector #421
Overall #2425
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #158
Healthcare Sector #421
Overall #2425
Revenue Q/Q Growth Statistics
High Average Low
921.55 % 73.48 % -84.51 %
(Jun 30 2021)  


AGRX's II. Quarter Q/Q Revenue Comment
Agile Therapeutics Inc achieved in the II. Quarter 2024 below company average Revenue growth of 0.79% quarter on quarter, to $ 5.08 millions.

Within Major Pharmaceutical Preparations industry 157 other companies have achieved higher Revenue quarter on quarter growth. While Agile Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 2425.


Agile Therapeutics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 19.72 $ 19.84 $ 18.62 $ 19.19 $ 16.01
Y / Y Revenue Growth (TTM) 23.22 % 53.35 % 71.03 % 128.39 % 139.36 %
Year on Year Revenue Growth Overall Ranking # 88 # 58 # 53 # 162 # 196
Seqeuential Revenue Change (TTM) -0.58 % 6.57 % -2.99 % 19.89 % 23.73 %
Seq. Revenue Growth (TTM) Overall Ranking # 566 # 481 # 348 # 668 # 1163


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2024 period, Agile Therapeutics Inc's cumulative twelve months Revenue were $ 20 millions, company would post below average annual Revenue growth of 23.73% year on year, if the fiscal year would end at Jun 30 2024.
A slow-down in the Agile Therapeutics Inc's Revenue growth from the 5.04% growth in Mar 31 2024.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 58 to 88.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 39
Overall # 88

Revenue TTM Y/Y Growth Statistics
High Average Low
165.4 %
 107.21 %
23.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 170
S&P 500 # 566
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2024 period, Agile Therapeutics Inc's cumulative twelve months Revenue were $ 20 millions, company would post below average annual Revenue growth of 23.22% year on year, if the fiscal year would end at Jun 30 2024.
A slow-down in the Agile Therapeutics Inc's Revenue growth from the 5.04% growth in Mar 31 2024.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 58 to 88.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 39
Overall # 88

Revenue TTM Y/Y Growth Statistics
High Average Low
165.4 %
107.21 %
23.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 170
S&P 500 # 566




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AGRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Organon and Co -0.06%$ -0.062 millions
Royalty Pharma Plc-0.17%$ -0.174 millions
Repligen Corp-0.21%$ -0.207 millions
Whitehawk Therapeutics Inc -0.37%$ -0.371 millions
3m Company-0.45%$ -0.446 millions
T2 Biosystems Inc -0.61%$ -0.611 millions
Hcw Biologics Inc -0.63%$ -0.635 millions
Enhabit Inc -0.65%$ -0.648 millions
Sonoma Pharmaceuticals Inc -1.05%$ -1.050 millions
Encision Inc -1.36%$ -1.358 millions
Vaso Corporation-1.40%$ -1.399 millions
Teladoc Health Inc -1.53%$ -1.527 millions
Zimvie Inc -1.55%$ -1.549 millions
Alpha Pro Tech Ltd -1.65%$ -1.645 millions
Novavax inc -2.11%$ -2.107 millions
Agile Therapeutics Inc-2.23%$ -2.232 millions
Fresenius Medical Care Ag-2.33%$ -2.330 millions
Avantor Inc -2.36%$ -2.357 millions
Aspira Women s Health inc -2.81%$ -2.810 millions
Viatris Inc -3.11%$ -3.113 millions
Catheter Precision Inc -3.13%$ -3.125 millions
Nrc Health-3.15%$ -3.153 millions
Akoya Biosciences Inc -3.16%$ -3.158 millions
Neuronetics Inc -3.55%$ -3.547 millions
Mettler toledo International Inc -3.60%$ -3.601 millions
Prestige Consumer Healthcare Inc -4.18%$ -4.181 millions
Dentsply Sirona Inc -4.28%$ -4.280 millions
Waters Corporation-4.33%$ -4.327 millions
Accelerate Diagnostics Inc -4.39%$ -4.394 millions
Envista Holdings Corporation-4.50%$ -4.499 millions


About Agile Therapeutics Inc Revenue Growth Rates (AGRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Agile Therapeutics Inc (CIK 1261249).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-24-011904
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Agile Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.